Análise de impacto do stent farmacológico no orçamento do sistema único de saúde

• Autor(a) principal: Araujo, Denizar Vianna [UNIFESP]
• Data de Publicação: 2007
• Outros Autores: Lima, Valter Correia [UNIFESP], Ferraz, Marcos Bosi [UNIFESP]
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S0066-782X2007000400016; http://repositorio.unifesp.br/handle/11600/3627
• topic: Stents - angioplasty, transluminal, percutaneous coronary; technology, high-cost; Angioplastia transluminal percutânea coronariana; tecnologia de alto custo

BACKGROUND: Drug-eluting stents represent an additional option to treat coronary artery disease. This technology represents a major breakthrough that may require additional funding in the short-term to enable its inclusion in procedures of the Unified Health System. OBJECTIVE: To estimate the impact on the Unified Health System budget in the first year of use of drug-eluting stents. METHODS: A Budget Impact Model was designed to predict the economic impact of the inclusion of drug-eluting stents in the Unified Health System budget. Data about costs and local procedures were collected in multiple sources, specifically procedure volume data, hospital costs, cost of stents, drug costs and number of stents used in single and multi-vessel procedures. RESULTS: The results in the first year indicate that the impact on the Unified Health System is of 12.8% in the best scenario and 24.4% in the worst scenario, representing an increase by R$ 24 to 44 million in the total projected budget. CONCLUSION: Drug-eluting stents have an additional cost compared with standard stents in the first year of use in the Unified Health System.